Economic uncertainty rose to record levels in the wake of the COVID-19 pandemic in the United States, fueled by concerns over the direct impact of the virus and the public policy response. Many uncertainty measures remain elevated relative to their pre-pandemic levels, even as the economy has recovered.

The authors examine the evolution of several uncertainty measures that are both forward-looking and available in near real-time. Their analysis benefits from real-time measures that supplement traditional macro indicators, which become available with lags of weeks or months. Forward-looking uncertainty measures gleaned from business decision makers prove especially useful for assessing prospective responses to a pandemic shock or other fast-moving developments.

In brief, the authors find the following:

  • Equity market traders and executives at nonfinancial firms have shared similar assessments about uncertainty at one-year look-ahead horizons. Put another way, the authors find that, contrary to the message in the popular press, they see little disconnect between “Main Street” and “Wall Street” views. 
  • The 1-month VIX (an index designed to show future market volatility), the Twitter-based Economic Uncertainty Index, and macro forecaster disagreement all rose sharply at the onset of the pandemic but retrenched almost completely by mid-2021. Thus, these measures exhibit a somewhat different time pattern than the one-year VIX and the authors’ survey-based measure of business-level uncertainty.
  • The newspaper-based Economic Policy Uncertainty Index shows that much of the initial pandemic-related surge in uncertainty reflected concerns around healthcare policy, which moderated post-vaccines, as well as fiscal policy and regulation. Rising inflation concerns and Russia’s invasion of Ukraine became important sources of uncertainty by 2022.
  • An analysis of the Survey of Business Uncertainty (SBU)1 reveals that firm-level risk perceptions shifted sharply to the upside beginning in the summer and fall of 2020 and continuing through March 2022, revealing that decision makers in nonfinancial businesses share some of the optimism that seems manifest in equity markets over this time. 
  • Special SBU questions reveal that recently high uncertainty levels are exerting only a mild restraint on capital investment plans for 2022 and 2023. This finding differs from earlier in the pandemic, when first-moment revenue expectations were softer and downside risks still loomed large. 

The authors note that these and other results illustrate the value of business surveys like the SBU that directly elicit own-firm forecast distributions and self-assessed effects of uncertainties on investment and other outcomes of interest. 


1 In partnership with Steven J. Davis of Chicago Booth and Nicholas Bloom of Stanford, the Federal Reserve Bank of Atlanta developed the Atlanta Fed/Chicago Booth/Stanford Survey of Business Uncertainty (SBU), a panel survey that measures one-year-ahead expectations and uncertainties that firms have about their own employment and sales. (atlantafed.org/research/surveys/business-uncertainty)

More on this topic

Interactive Research Briefs·May 14, 2024

Return to Office and the Tenure Distribution

Austin Wright, David Van Dijcke, and Florian Gunsilius
Return-to-office (RTO) mandates drive employees away from firms, with senior employees leaving at the highest rates, likely leading to significant human capital costs in terms of output, productivity, innovation, and competitiveness for the companies implementing strict RTO policies.
Topics: COVID-19, Employment & Wages
Research Briefs·Mar 7, 2024

What Drives Inflation? Lessons from Disaggregated Price Data

Elisa Rubbo
US inflation in the early phases of the COVID pandemic was entirely driven by disruptions in supply and demand across industries, whereas most of the subsequent increase in consumer prices is driven by aggregate demand.
Topics: COVID-19, Monetary Policy
Research Briefs·Feb 1, 2024

Quantifying the Social Value of a Universal COVID-19 Vaccine and Incentivizing Its Development

Rachel Glennerster, Thomas Kelly, Claire T. McMahon, and Christopher M. Snyder
A universal COVID-19 vaccine that is effective against existing and future variants could provide the United States population with $1.5–$2.6 trillion more in social value than variant-specific boosters. The social value of a universal vaccine eclipses the cost of incentivizing...
Topics: COVID-19